Highlights First Wave BioPharma, Inc.

Equities

FWBI

US33749P4081

Delayed Nasdaq Other stock markets 12:48:14 2024-04-29 pm EDT			5-day change	1st Jan Change
2.84 ^USD	+3.65%		-2.41%	-32.38%

Mar. 29	First Wave BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 14	Sector Update: Health Care Stocks Retreating Late Afternoon	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

First Wave BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Inflation Data	Mar. 14	MT
First Wave BioPharma, Inc. completed the acquisition of ImmunogenX, LLC for approximately $3 million.	Mar. 12	CI
First Wave BioPharma Investors Exercise Warrants at Reduced Price -- Shares Up	Dec. 27	MT
First Wave BioPharma Shares Skyrocket After Selling Prospective Treatment for Inflammatory Bowel Diseases	Dec. 27	MT
First Wave BioPharma, Inc. signed a non-binding term sheet to acquire ImmunogenX, LLC.	Dec. 17	CI
First Wave BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
First Wave BioPharma Signs License Agreement With Sanofi for Capeserod	23-09-14	MT
First Wave Biopharma, Inc. Announces Exclusive Global License Agreement for Capeserod from Sanofi	23-09-14	CI
First Wave BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
First Wave BioPharma, Inc. Announces Initial Topline Results from Phase 2 Span Clinical Trial Investigating Enhanced Adrulipase Formulation	23-07-13	CI
First Wave BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
First Wave Biopharma Completes Patient Screening for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis	23-05-11	CI
First Wave BioPharma, Inc. Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis	23-04-25	CI
First Wave BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
First Wave Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
First Wave BioPharma, Inc. Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation	23-03-09	CI
First Wave BioPharma, Inc. Announces Phase 2 Adrulipase Combination Trial Data	23-02-21	CI
First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis	23-02-02	CI
First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis	23-01-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights First Wave BioPharma, Inc.

Equities

FWBI

US33749P4081

Highlights

Filters